NASDAQ:NVCR - NovoCure Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Hold
Consensus Price Target: $195.71
Forecasted Upside: -13.24 %
Number of Analysts: 9
Breakdown:
1 Sell Ratings
4 Hold Ratings
4 Buy Ratings
0 Strong Buy Ratings

^$225.58 As of 06/23/2021 01:00 AM ET

▲ +1.15 (0.51%)

1 month | 3 months | 12 months

Get New NovoCure Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for NVCR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NVCR

^$195.71

▼ -13.24% Downside Potential

This price target is based on 9 analysts offering 12 month price targets for NovoCure in the last 3 months. The average price target is $195.71, with a high forecast of $250.00 and a low forecast of $142.00. The average price target represents a -13.24% upside from the last price of $225.58.

Current Consensus is Hold

The current consensus among 9 investment analysts is to hold stock in NovoCure. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations Description Skip Past Price Target Consensus Chart

0 strong buy ratings
2 buy ratings
3 hold ratings
1 sell ratings

Ratings as of

12/31/2019

0 strong buy ratings
2 buy ratings
3 hold ratings
1 sell ratings

Ratings as of

3/30/2020

0 strong buy ratings
3 buy ratings
3 hold ratings
2 sell ratings

Ratings as of

6/28/2020

0 strong buy ratings
4 buy ratings
4 hold ratings
2 sell ratings

Ratings as of

9/26/2020

0 strong buy ratings
4 buy ratings
4 hold ratings
2 sell ratings

Ratings as of

12/25/2020

0 strong buy ratings
4 buy ratings
3 hold ratings
2 sell ratings

Ratings as of

3/25/2021

0 strong buy ratings
4 buy ratings
4 hold ratings
1 sell ratings

Ratings as of

5/24/2021

0 strong buy ratings
4 buy ratings
4 hold ratings
1 sell ratings

Ratings as of

6/23/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/20/2021	Wedbush	Reiterated Rating	Neutral ➝ Underperform	$159.00 ➝ $154.00	Low
4/19/2021	Truist	Boost Price Target		$132.00 ➝ $142.00	Medium
4/19/2021	Truist Securities	Boost Price Target	Hold	$132.00 ➝ $142.00	Low
4/14/2021	Northland Securities	Boost Price Target	Outperform	$200.00 ➝ $250.00	Medium
4/14/2021	Wedbush	Downgrade	Neutral ➝ Underperform	$159.00 ➝ $154.00	Medium
4/14/2021	Mizuho	Boost Price Target	Positive ➝ Buy	$175.00 ➝ $242.00	Medium
4/13/2021	Wells Fargo & Company	Boost Price Target	Positive ➝ Equal Weight	$135.00 ➝ $215.00	High
3/1/2021	Mizuho	Boost Price Target	Buy	$150.00 ➝ $175.00	Low
1/29/2021	Truist	Boost Price Target		$118.00 ➝ $132.00	Low
1/25/2021	Piper Sandler	Boost Price Target	Overweight	$140.00 ➝ $225.00	Low
1/12/2021	Wedbush	Boost Price Target		$110.00 ➝ $159.00	Medium
10/30/2020	Mizuho	Boost Price Target	Buy	$84.00 ➝ $150.00	Low
10/29/2020	Piper Sandler	Boost Price Target	Overweight	$125.00 ➝ $140.00	Medium
9/23/2020	Northland Securities	Initiated Coverage	Outperform		Low
9/18/2020	Wells Fargo & Company	Downgrade	Overweight ➝ Equal Weight	$116.00	High
9/17/2020	Piper Sandler	Boost Price Target		$89.00 ➝ $125.00	Low
9/17/2020	Truist	Downgrade	Buy ➝ Hold	$108.00	High
8/3/2020	SunTrust Banks	Reiterated Rating	Buy		Medium
7/31/2020	Wedbush	Reiterated Rating	Neutral		Low
7/31/2020	Mizuho	Boost Price Target	Buy	$82.00 ➝ $84.00	Medium
7/30/2020	Oppenheimer	Reiterated Rating	Hold		Medium
7/30/2020	Piper Sandler	Boost Price Target		$85.00 ➝ $89.00	Low
7/6/2020	Mizuho	Reiterated Rating	Buy	$82.00	Medium
6/1/2020	Oppenheimer	Initiated Coverage	Buy		Low
5/27/2020	Mizuho	Reiterated Rating	Buy	$82.00	High
5/1/2020	SunTrust Banks	Lower Price Target	Buy	$105.00 ➝ $90.00	High
5/1/2020	Wedbush	Lower Price Target	Neutral	$80.00 ➝ $78.00	High
5/1/2020	Oppenheimer	Downgrade	Outperform ➝ Market Perform		High
5/1/2020	Oppenheimer	Reiterated Rating	Outperform ➝ Market Perform	$102.00 ➝ $78.00	High
4/19/2020	Piper Sandler	Initiated Coverage	Overweight	$85.00	High
4/19/2020	Evercore ISI	Downgrade	In-Line ➝ Underperform		High
4/9/2020	Evercore ISI	Downgrade	In-Line ➝ Underperform	$75.00 ➝ $58.00	Medium
4/8/2020	Mizuho	Lower Price Target	Buy	$91.00 ➝ $82.00	High
4/7/2020	Piper Sandler	Initiated Coverage	Overweight	$85.00	High
4/7/2020	Wells Fargo & Company	Lower Price Target	Overweight	$90.00 ➝ $82.00	High
3/5/2020	Wells Fargo & Company	Upgrade	Equal Weight ➝ Overweight	$85.00 ➝ $90.00	Low
2/28/2020	Mizuho	Reiterated Rating	Buy	$91.00	High
1/14/2020	JPMorgan Chase & Co.	Reiterated Rating	Hold		Medium
1/7/2020	Mizuho	Reiterated Rating	Buy	$91.00	High
12/12/2019	Wells Fargo & Company	Boost Price Target		$75.00 ➝ $85.00	High
11/4/2019	JPMorgan Chase & Co.	Reiterated Rating	Hold	$79.00	High
9/13/2019	Oppenheimer	Boost Price Target	Buy	$85.00 ➝ $97.00	Low
7/29/2019	SunTrust Banks	Upgrade	Hold ➝ Buy		Medium
7/26/2019	Oppenheimer	Set Price Target	Buy	$85.00	N/A
7/26/2019	Wedbush	Downgrade	Outperform ➝ Neutral	$57.00 ➝ $80.00	High
7/26/2019	JPMorgan Chase & Co.	Downgrade	Overweight ➝ Neutral	$61.00 ➝ $79.00	High
7/26/2019	Mizuho	Boost Price Target	Buy	$63.00 ➝ $91.00	High
7/19/2019	Oppenheimer	Set Price Target	Buy	$76.00	Medium
6/28/2019	Oppenheimer	Initiated Coverage	Outperform	$75.00 ➝ $75.00	High
5/26/2019	JPMorgan Chase & Co.	Reiterated Rating	Buy		Medium
5/24/2019	Wedbush	Reiterated Rating	Outperform	$57.00	High
3/19/2019	SunTrust Banks	Initiated Coverage	Hold ➝ Hold	$50.00	High
3/7/2019	Mizuho	Reiterated Rating	Buy	$63.00	Low
2/28/2019	Wells Fargo & Company	Reiterated Rating	Hold		High
12/6/2018	Mizuho	Reiterated Rating	Buy	$51.00	Low
11/15/2018	Mizuho	Reiterated Rating	Buy	$51.00	Low
11/2/2018	Wells Fargo & Company	Downgrade	Outperform ➝ Market Perform		Medium
11/1/2018	Mizuho	Reiterated Rating	Buy	$51.00	Medium
10/30/2018	Wells Fargo & Company	Reiterated Rating	Outperform ➝ Market Perform	$41.00 ➝ $36.00	Medium
10/26/2018	Wedbush	Boost Price Target	Outperform	$55.00 ➝ $58.00	Medium
10/19/2018	Mizuho	Reiterated Rating	Buy	$58.00	High
9/20/2018	Deutsche Bank Aktiengesellschaft	Set Price Target	Hold	$44.00	Low
9/19/2018	Wells Fargo & Company	Boost Price Target	Outperform ➝ Positive	$53.00 ➝ $58.00	High
9/16/2018	JPMorgan Chase & Co.	Reiterated Rating	Buy		Medium
9/13/2018	Wells Fargo & Company	Reiterated Rating	Buy		Low
9/7/2018	Wedbush	Reiterated Rating	Outperform	$50.00 ➝ $40.00	High
9/6/2018	Wells Fargo & Company	Boost Price Target	Outperform ➝ Outperform	$40.00 ➝ $48.00	High
9/6/2018	Mizuho	Reiterated Rating	Buy	$58.00	High
7/27/2018	Wedbush	Boost Price Target	Outperform ➝ Outperform	$33.00 ➝ $40.00	Low
7/27/2018	JPMorgan Chase & Co.	Boost Price Target	Overweight ➝ Overweight	$30.00 ➝ $44.00	High
7/25/2018	Deutsche Bank Aktiengesellschaft	Downgrade	Buy ➝ Hold		Low
7/16/2018	Evercore ISI	Initiated Coverage	Outperform	$46.00	High
6/13/2018	Mizuho	Reiterated Rating	Buy	$32.00	Low
4/27/2018	Wedbush	Boost Price Target	Outperform ➝ Outperform	$29.00 ➝ $33.00	Low
4/19/2018	Deutsche Bank Aktiengesellschaft	Upgrade	Hold ➝ Buy	$23.80 ➝ $19.00	Low
4/18/2018	Mizuho	Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $32.00	High
2/23/2018	Deutsche Bank Aktiengesellschaft	Lower Price Target	Hold ➝ Hold	$22.00 ➝ $19.00	High
2/23/2018	Mizuho	Reiterated Rating	Buy ➝ Buy	$25.00 ➝ $28.00	High
12/1/2017	Mizuho	Reiterated Rating	Buy	$25.00	High
11/20/2017	JPMorgan Chase & Co.	Reiterated Rating	Buy		N/A
10/27/2017	Wedbush	Reiterated Rating	Outperform	$29.00 ➝ $25.00	N/A
9/6/2017	Mizuho	Initiated Coverage	Buy	$25.00	Medium
7/17/2017	Deutsche Bank Aktiengesellschaft	Reiterated Rating	Hold	$18.00 ➝ $19.00	Low
5/24/2017	Wells Fargo & Company	Upgrade	Market Perform ➝ Outperform	$15.00	High
5/1/2017	JPMorgan Chase & Co.	Reiterated Rating	Buy	$14.00	High
4/28/2017	Deutsche Bank Aktiengesellschaft	Boost Price Target	Hold	$10.00 ➝ $11.00	Low
4/27/2017	Wedbush	Reiterated Rating	Outperform	$20.00	Low
4/18/2017	Aegis	Reiterated Rating	Buy	$14.00	Low
4/7/2017	Wedbush	Reiterated Rating	Outperform	$20.00	Low
4/4/2017	JMP Securities	Reiterated Rating	Outperform	$34.00	High
3/28/2017	Aegis	Reiterated Rating	Buy	$14.00	High
2/26/2017	JPMorgan Chase & Co.	Reiterated Rating	Buy	$14.00	N/A
1/11/2017	Wells Fargo & Company	Downgrade	Outperform ➝ Market Perform		N/A
1/11/2017	Wedbush	Reiterated Rating	Outperform	$20.00	N/A
12/21/2016	Wedbush	Reiterated Rating	Outperform	$20.00	N/A
12/13/2016	Wedbush	Reiterated Rating	Outperform	$20.00	N/A
11/18/2016	Wedbush	Reiterated Rating	Outperform	$20.00	N/A
11/2/2016	JPMorgan Chase & Co.	Set Price Target	Buy	$14.00	N/A
7/29/2016	JPMorgan Chase & Co.	Lower Price Target	Overweight	$29.00 ➝ $14.00	N/A
7/29/2016	JMP Securities	Lower Price Target	Market Outperform	$43.00 ➝ $34.00	N/A
7/29/2016	Deutsche Bank Aktiengesellschaft	Lower Price Target	Hold	$28.00 ➝ $16.00	N/A
7/29/2016	Barclays	Lower Price Target	Underweight	$12.00 ➝ $9.00	N/A
7/29/2016	Wedbush	Lower Price Target	Outperform	$30.00 ➝ $20.00	N/A
7/6/2016	Wedbush	Reiterated Rating	Outperform	$30.00	N/A

(Data available from 6/23/2016 forward)

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and Optune Lua, a Tumor Treating Fields delivery system for use as a monotherapy treatment for adult patients with glioblastoma. It is also developing products for brain metastases, non-small cell lung cancer, pancreatic cancer, gastric cancer, ovarian cancer, liver cancer, and mesothelioma. The company markets its products in the European Union, Japan, and internationally. It has a clinical trial collaboration agreement with MSD to evaluate tumor treating fields together with KEYTRUDA, an anti-PD-1 therapy; and a strategic alliance with the NYU Grossman School of Medicine's Department of Radiation Oncology that provides a framework for preclinical and clinical development projects studying Tumor Treating Fields. NovoCure Limited was founded in 2000 and is based in Saint Helier, Jersey.

Today's Range

Now: $225.58

$223.95

$227.66

50 Day Range

MA: $200.74

$173.04

$225.58

52 Week Range

Now: $225.58

$55.40

$228.10

Volume

441,996 shs

Average Volume

886,851 shs

Market Capitalization

$23.33 billion

P/E Ratio

2,050.91

Dividend Yield

N/A

Beta

1.08

Frequently Asked Questions

What sell-side analysts currently cover shares of NovoCure?

The following sell-side analysts have issued stock ratings on NovoCure in the last year: Mizuho, Northland Securities, Oppenheimer Holdings Inc., Piper Sandler, SunTrust Banks, Inc., TheStreet, Truist, Truist Securities, Wedbush, Wells Fargo & Company, and Zacks Investment Research.
View the latest analyst ratings for NVCR.

What is the current price target for NovoCure?

7 Wall Street analysts have set twelve-month price targets for NovoCure in the last year. Their average twelve-month price target is $195.71, suggesting a possible downside of 12.8%. Northland Securities has the highest price target set, predicting NVCR will reach $250.00 in the next twelve months. Truist has the lowest price target set, forecasting a price of $142.00 for NovoCure in the next year.
View the latest price targets for NVCR.

What is the current consensus analyst rating for NovoCure?

NovoCure currently has 1 sell rating, 4 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in NVCR, but not buy more shares or sell existing shares.
View the latest ratings for NVCR.

What other companies compete with NovoCure?

Other companies that are similar to NovoCure include Becton, Dickinson and, Boston Scientific, DexCom, Baxter International, ResMed, Fresenius SE & Co. KGaA, Teleflex, Insulet, Abiomed, Penumbra, Hill-Rom, Globus Medical, ShockWave Medical, Nevro and Tandem Diabetes Care.

How do I contact NovoCure's investor relations team?

NovoCure's physical mailing address is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. The medical equipment provider's listed phone number is 44-0-15-3475-6700 and its investor relations email address is [email protected] The official website for NovoCure is www.novocure.com.